» Articles » PMID: 34358653

Mechanism Deconvolution of Qing Fei Pai Du Decoction for Treatment of Coronavirus Disease 2019 (COVID-19) by Label-free Integrative Pharmacology Assays

Overview
Date 2021 Aug 6
PMID 34358653
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Ethnopharmacological Relevance: Traditional Chinese medicine (TCM) has a long history in the prevention and treatment of pandemics. The TCM formula Lung Cleansing and Detoxifying Decoction (LCDD), also known as Qing Fei Pai Du Decoction, has been demonstrated effective against Coronavirus Disease 2019 (COVID-19).

Aim Of The Study: This work aimed to elucidate the active ingredients, targets and pathway mechanism of LCDD related to suppression of inflammatory, immunity regulation and relaxation of airway smooth muscle for the treatment of COVID-19.

Materials And Methods: Mining chemical ingredients reported in LCDD, 144 compounds covering all herbs were selected and screened against inflammatory-, immunity- and respiratory-related GPCRs including GPR35, H1, CB2, B2, M3 and β2-adrenoceptor receptor using a label-free integrative pharmacology method. Further, all active compounds were detected using liquid chromatography-tandem mass spectrometry, and an herb-compound-target network based on potency and content of compounds was constructed to elucidate the multi-target and synergistic effect.

Results: Thirteen compounds were identified as GPR35 agonists, including licochalcone B, isoliquiritigenin, etc. Licochalcone B, isoliquiritigenin and alisol A exhibited bradykinin receptor B2 antagonism activities. Atractyline and shogaol showed as a cannabinoid receptor CB2 agonist and a histamine receptor H1 antagonist, respectively. Tectorigenin and aristofone acted as muscarinic receptor M3 antagonists, while synephrine, ephedrine and pseudoephedrine were β2-adrenoceptor agonists. Pathway deconvolution assays suggested activation of GPR35 triggered PI3K, MEK, JNK pathways and EGFR transactivation, and the activation of β2-adrenoceptor mediated MEK and Ca. The herb-compound-target network analysis found that some compounds such as licochalcone B acted on multiple targets, and multiple components interacted with the same target such as GPR35, reflecting the synergistic mechanism of Chinese medicine. At the same time, some low-abundance compounds displayed high target activity, meaning its important role in LCDD for anti-COVID-19.

Conclusions: This study elucidates the active ingredients, targets and pathways of LCDD. This is useful for elucidating multitarget synergistic action for its clinical therapeutic efficacy.

Citing Articles

Exploring the mechanism of Radix Bupleuri in the treatment of depression combined with SARS-CoV-2 infection through bioinformatics, network pharmacology, molecular docking, and molecular dynamic simulation.

Chen Z, Wang X, Huang W Metab Brain Dis. 2025; 40(1):105.

PMID: 39832077 DOI: 10.1007/s11011-025-01536-7.


Recent advancements in traditional Chinese medicine for COVID-19 with comorbidities across various systems: a scoping review.

Shang X, Cao Y, Guo Y, Zhang L, Li J, Zhang H Infect Dis Poverty. 2024; 13(1):97.

PMID: 39696533 PMC: 11658301. DOI: 10.1186/s40249-024-01263-8.


Jinhua Qinggan Granule UHPLC-Q-extractive-Orbitrap-MS assay: Putative identification of 45 potential anti-Covid-19 constituents, confidential addition, and pharmacopoeia quality-markers recommendation.

Zeng J, Li X, Cai R, Li C, Chen S J Food Drug Anal. 2024; 31(3):534-551.

PMID: 39666276 PMC: 10629912. DOI: 10.38212/2224-6614.3466.


Cytokine Storm in COVID-19: Insight into Pathological Mechanisms and Therapeutic Benefits of Chinese Herbal Medicines.

Yu Q, Zhou X, Kapini R, Arsecularatne A, Song W, Li C Medicines (Basel). 2024; 11(7).

PMID: 39051370 PMC: 11270433. DOI: 10.3390/medicines11070014.


Chinese Medicine for Treatment of COVID-19: A Review of Potential Pharmacological Components and Mechanisms.

Xu Q, Yu D, Fan X, Cui H, Dai Q, Zhong X Chin J Integr Med. 2024; 31(1):83-95.

PMID: 38958885 DOI: 10.1007/s11655-024-3909-z.


References
1.
Zhou H, Peng X, Hou T, Zhao N, Qiu M, Zhang X . Identification of novel phytocannabinoids from Ganoderma by label-free dynamic mass redistribution assay. J Ethnopharmacol. 2019; 246:112218. DOI: 10.1016/j.jep.2019.112218. View

2.
Pera T, Penn R . Crosstalk between beta-2-adrenoceptor and muscarinic acetylcholine receptors in the airway. Curr Opin Pharmacol. 2014; 16:72-81. PMC: 4096844. DOI: 10.1016/j.coph.2014.03.005. View

3.
Zhao J, Tian S, Lu D, Yang J, Zeng H, Zhang F . Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei-Pai-Du decoction in the treatment of COVID-19. Phytomedicine. 2020; 85:153315. PMC: 7480398. DOI: 10.1016/j.phymed.2020.153315. View

4.
Schroder R, Schmidt J, Blattermann S, Peters L, Janssen N, Grundmann M . Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat Protoc. 2011; 6(11):1748-60. DOI: 10.1038/nprot.2011.386. View

5.
Taniguchi Y, Tonai-Kachi H, Shinjo K . 5-Nitro-2-(3-phenylpropylamino)benzoic acid is a GPR35 agonist. Pharmacology. 2008; 82(4):245-9. DOI: 10.1159/000157625. View